ACCESSWIRE
31 Jan 2023, 19:43 GMT+10
LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International (STO:BINV)
Lund, Sweden, January 31, 2023 - BioInvent International AB ('BioInvent') (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per January 31, 2023 amounts to 65,804,362 shares, corresponding to an equal number of votes.
The increase in the number of shares and votes results from the directed issue of USD 3 million (approximately SEK 31 million) to Leukemia & Lymphoma Society's Therapy Acceleration Program® (LLS TAP) by issuance of 836,478 shares, announced on January 17, 2023 in connection with BioInvent entered into a partnership with LLS TAP.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
This information is information that BioInvent International is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-01-31 10:00 CET.
Attachments
Change in the number of shares and votes in BioInvent International AB
SOURCE: BioInvent International
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationBEIJING, China: After more than a year of self-imposed exile overseas, Alibaba founder Jack Ma has returned to China, allegedly ...
NEW YORK, New York - U.S. stocks and the dollar made solid gains on Wednesday as banking sector fears continued ...
NEW YORK CITY, New York: In a legal filing, Twitter announced that parts of its source code - the fundamental ...
NEW YORK CITY, New York: Bloomberg News has reported that New Jersey-based Valley National Bancorp is bidding to purchase Silicon ...
NEW YORK, New York - U.S. stocks lipped on Tuesday as bond yields rose in the aftermath of the easing ...
DUBLIN, Ireland: US pharmaceutical giant Eli Lilly has said it will build a $1bn medicine manufacturing site in Limerick. Lily ...
OTTAWA, Canada: After a meeting between Canadian Prime Minister Justin Trudeau and US President Joe Biden, Ottawa has pledged to ...
WASHINGTON D.C.: The US Supreme Court has ruled that a deaf student in Michigan can sue his public school district, ...
San Diego Padres third-base coach Matt Williams has been diagnosed with colon cancer and will be away from the team ...
Free agent wideout Marvin Jones took to social media Wednesday to announce he's returning to the Detroit Lions, a team ...
The New Jersey Devils and the New York Rangers handled their initial games after clinching a playoff berth in significantly ...
Army named Butler assistant Kevin Kuwik as its next head coach on Wednesday. Kuwik has more than 20 years' experience ...